OMP-131R10: Interim Ph Ia/Ib data

Interim data from 11 evaluable patients with advanced solid tumors in the Phase Ia portion of an open-label, dose-escalation, U.S. Phase Ia/Ib trial showed that 2.5-15 mg/kg doses of IV OMP-13R10 ever...